HLUBF Financial Statements From 2010 to 2025
| HLUBF Stock | USD 5.35 0.00 0.00% |
Check H Lundbeck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among H Lundbeck's main balance sheet or income statement drivers, such as , as well as many indicators such as . HLUBF financial statements analysis is a perfect complement when working with H Lundbeck Valuation or Volatility modules.
HLUBF |
H Lundbeck AS Company Profit Margin Analysis
H Lundbeck's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current H Lundbeck Profit Margin | 0.10 % |
Most of H Lundbeck's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, H Lundbeck AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, H Lundbeck AS has a Profit Margin of 0.105%. This is 100.94% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 108.27% lower than that of the firm.
H Lundbeck AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining H Lundbeck's current stock value. Our valuation model uses many indicators to compare H Lundbeck value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across H Lundbeck competition to find correlations between indicators driving H Lundbeck's intrinsic value. More Info.H Lundbeck AS is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.48 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for H Lundbeck AS is roughly 2.08 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the H Lundbeck's earnings, one of the primary drivers of an investment's value.About H Lundbeck Financial Statements
H Lundbeck stakeholders use historical fundamental indicators, such as H Lundbeck's revenue or net income, to determine how well the company is positioned to perform in the future. Although H Lundbeck investors may analyze each financial statement separately, they are all interrelated. For example, changes in H Lundbeck's assets and liabilities are reflected in the revenues and expenses on H Lundbeck's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in H Lundbeck AS. Please read more on our technical analysis and fundamental analysis pages.
Lundbeck AS, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company was founded in 1915 and is headquartered in Valby, Denmark. H Lundbeck operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5437 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in HLUBF Pink Sheet
H Lundbeck financial ratios help investors to determine whether HLUBF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLUBF with respect to the benefits of owning H Lundbeck security.